Dr. Eileen O’Meara is a Professor at the Department of Medicine at the Université de Montréal and practices cardiology at the Montreal Heart Institute. She pursued a Fellowship in Heart Failure at the Western Infirmary & Glasgow Royal Infirmary in the UK, and another in Stress Echocardiography and Tissue Doppler at Hôpital Européen Georges Pompidou in Paris.
Dr. O’Meara oversaw resident training/teaching at the Montreal Heart Institute’s Echocardiography Laboratory from 2007 to 2010. She is a member of the Internal Review Board for Research at the Montreal Heart Institute and the Chief of Outpatients Clinics at MHI. She served as Co-Chair of the Primary Panel for the CCC Heart Failure Guidelines from 2016 to 2019. She is a Reviewer for the Canadian Journal of Cardiology, the European Heart Journal, the European Journal of Heart Failure, Circulation and Circulation: Heart Failure (member of the editorial board for the latter), among others, and does abstract grading for the European Society of Cardiology and CCC meetings. Her research focuses on remodeling and fibrosis biomarkers in HF, including cardiac imaging biomarkers; as well as on comorbid conditions that contribute to HF, including diabetes, CKD and anemia.
Dr. O’Meara was a Canadian National Lead Investigator for the PARAGON-HF and for the DAPA-HF trials, and currently is a National Lead Investigator for the DELIVER trial. She is a member of the Steering Committees for the GALACTIC-HF, the HEART-FID and the DAPA-ACT trials.